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We identified ubiquitin-like with PHD andRING finger
domain 1 (UHRF1) as a binding factor for DNA
interstrand crosslink (ICL) lesions through affinity pu-
rification of ICL-recognition activities. UHRF1 is re-
cruited to DNA lesions in vivo and binds directly to
ICL-containing DNA. UHRF1-deficient cells display
increased sensitivity to a variety of DNA damages.
We found that loss of UHRF1 led to retarded lesion
processing and reduced recruitment of ICL repair nu-
cleases to the site of DNA damage. UHRF1 interacts
physically with both ERCC1 and MUS81, two nucle-
ases involved in the repair of ICL lesions. Depletion
of both UHRF1 and components of the Fanconi ane-
mia (FA) pathway resulted in increased DNA damage
sensitivity compared to defect of each mechanism
alone. These results suggest that UHRF1 promotes
recruitment of lesion-processing activities via its
affinity to recognize DNA damage and functions as
a nuclease recruitment scaffold in parallel to the FA
pathway.
INTRODUCTION
The DNA interstrand crosslink (ICL) is a complex DNA lesion
arising from a variety of extrinsic and intrinsic bifunctional alky-
lating agents. ICL-inducing agents exhibit profound cytotoxicity
and are among the most widely used chemotherapy drugs
(McHugh et al., 2001). Deficiencies in repairing DNA ICLs
have severe pathological consequences, as highlighted by the
recessively inherited cancer-prone disease Fanconi anemia
(FA) (D’Andrea, 2010; Kim and D’Andrea, 2012).
Repair of DNA ICLs is accomplished by two distinct pathways.
The replication-dependent pathway operates primarily during
S phase and is initiated by replication fork encountering with
an ICL. Given that the formation of an ICL compromises both
strands of the double helix, error-free repair most likely involvesCellhomologous recombination with the undamaged sister chro-
matid upon formation of DNA strand breaks (Knipscheer et al.,
2009; Long et al., 2011). Consistently, defects in homologous
recombination factors such as Brca2, Rad51C, and BACH1
render cells sensitive to crosslinking agents. On the other
hand, ICLs in G1 and G0 phases or during early S phase of the
cell cycle utilize a recombination-independent mechanism
involving the combined actions of the nucleotide excision repair
and lesion bypass synthesis (Sarkar et al., 2006; Williams et al.,
2012; Zheng et al., 2003).
A key step in ICL repair is the loading of the appropriate
nucleases to the damaged site to achieve the initial incision
and unhooking of an ICL. Genetic and biochemical studies
have identified several nucleases including ERCC1-XPF,
MUS81-EME1, and SNM1A (Hodskinson et al., 2014; Wang
et al., 2011) in the nucleolytic processing of ICLs. These
structural-specific endonucleases act at different stages of ICL
removal, generating intermediates of single- or double-strand
breaks adjacent to the ICL lesion and allowing subsequent lesion
bypass and homologous recombination to take place (Bhagwat
et al., 2009; Hodskinson et al., 2014). However, the molecular
mechanisms directing the recruitment of nucleases to the
damaged sites are poorly understood. The main function of the
FA pathway is presumed to be the loading of lesion-processing
nucleases via FAND2/I monoubiquitination-mediated regulation
of the SLX4/FANCP nuclease scaffold (Guervilly et al., 2015;
Mun˜oz et al., 2009; Ouyang et al., 2015; Smogorzewska et al.,
2010; Stoepker et al., 2011; Svendsen et al., 2009). However, it
is unclear whether ICL-processing activities can be recruited
through other mechanisms.
Ubiquitin-like with PHD andRING finger domain 1 (UHRF1) is a
multi-domain protein important for the maintenance of cytosine
methylation. It recognizes specific forms of histone modifica-
tions and DNA hemimethylation (Liu et al., 2013; Nishiyama
et al., 2013) and facilitates the recruitment of Dnmt1 in order to
catalyze the methylation reaction on hemimethylated CpG mo-
tifs. As expected, cells defective in UHRF1 have reduced ampli-
tude and site accuracy of DNAmethylation (Bostick et al., 2007).
However, UHRF1 loss also causes cellular sensitivity to DNA-
damaging agents (Muto et al., 2002). Mechanistic insights onReports 10, 1957–1966, March 31, 2015 ª2015 The Authors 1957
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Figure 1. Identification of UHRF1 as an ICL-Interacting Protein
(A) A schematic of pull-down- and mass spectrometry-based purification of ICL-binding proteins. The 120-bp crosslinked substrate contains two psoralen ICLs
at defined positions and is end-labeled with biotin for the pull-down assay.
(B) Candidate ICL-binding proteins identified by mass spectrometry analyses using two independent ICL-containing DNA substrates.
(C) Time-lapse images showing recruit of GFP-tagged UHRF1 to laser-localized psoralen ICLs in U2OS cell nuclei at indicated time points.
(D) Imaging quantification of nuclear strip intensity of GFP-tagged UHRF1 to laser-localized psoralen ICLs in U2OS cells.
(legend continued on next page)
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this unexpected phenotype are unknown. In this report, we
identified UHRF1 as an ICL-binding protein through an unbiased
affinity purification of lesion-binding activities. Analyses of
UHRF1-deficient cells revealed an unanticipated defect in lesion
processing. We found that URHF1 interacts with lesion-process-
ing nucleases ERCC1 and MUS81 and may serve as a recruit-
ment factor for the repair of DNA lesions. These results suggest
a UHRF1-dependent mechanism of directing structure-specific
nucleases to the site of DNA damage.
RESULTS
Identification of UHRF1 as an ICL-Binding Protein
To isolate proteins that bind to DNA ICLs, we designed a 120-bp
oligonucleotide duplex that has two TA nucleotide residues for
the formation of site-specific, psoralen-based ICLs (Figures 1A
and S1A). Upon psoralen and UVA treatment, crosslinked oligos
were purified, end-labeled with biotin, and used as the cross-
linked substrate for ICL-affinity purification. A control substrate
was generated in parallel without the addition of psoralen. The
crosslinked and control substrates were attached to streptavidin
beads and incubated with HeLa nuclear extracts. Tightly bound
proteins were eluded and subjected to mass spectrometry ana-
lyses. The amount of each protein bound to crosslinked sub-
strate was normalized to that of the control substrate in order
to yield a ratio (crosslinked:control) as a reflection of its affinity
to the ICL. As shown in Figure 1B, we found that the UHRF1 pro-
tein is highly enriched by the crosslinked substrate.
To exclude the possibility that the identification of UHRF1
was biased toward sequence composition, we repeated the
pull-down experiment with a second set of crosslinked and con-
trol substrates (substrate B, Figure S1A) in which only the two TA
motifs and their relative positions are identical to the original
substrate (substrate A). UHRF1 was again identified as the top
candidate, suggesting that binding of UHRF1 to ICL-containing
DNAdoes not rely on the sequence context of the ICL substrates.
To test whether UHRF1 binds to ICLs in vivo, laser-localized
psoralen ICLs were introduced into the nuclei of U2OS cells
(Muniandy et al., 2009) expressing GFP-UHRF1. Beginning at
30 s after ICL induction, GFP-UHRF1 accumulated at the ICL
track and appeared to peak around 8 min (Figures 1C and 1D).
This result indicates that UHRF1 is specifically enriched at the
sites of ICL lesions and that its recruitment is an early event in
ICL response in comparison to the recruitment of FANCA (Yan
et al., 2012).
Next, we performed the episomal chromatin immunoprecipia-
tion (eChIP) assay (Shen et al., 2009) with psoralen- or cisplatin-
derived ICL lesions. TheeChIPsubstrate contains adefinedpsor-
alen ICL positioned 488 bases downstream of the Epstein-Barr
virus (EBV) replication origin (Figures S1B and 1C). Therefore,
protein recruitment to the site of the ICL can be analyzed in the(E) Top: Schematic representation of the DNA substrate used in the eChIP assay. T
the direction of replication fork movement. Small arrows indicate the region of qPC
protein in 293 and 293EBNA cells. Error bars are SD from four independent expe
(F) Top: Schematic representation of the DNA substrates used in the eChIP assay
region of qPCR amplification. Bottom: eChIP assay measuring the recruitment of
represent average distributions. Error bars are SD from three independent exper
Cellabsence or presence of DNA replication to determine whether a
blocked replication fork is required. We found that the presence
of a single-defined psoralen ICL yielded significant UHRF1
enrichment onto the crosslinked substrate (Figure 1E). The
enrichment was not significantly increased when substrate repli-
cation was enabled in the 293EBNA cells, suggesting that stalled
replication fork is not essential for UHRF1 binding to the ICL. The
increased UHRF1 recruitment in both control and ICL substrates
mostly likely reflects a replication-coupled enrichment of UHRF1
(Nishiyama et al., 2013). Consistently, the eChIP substrate con-
taining randomly introduced cisplatin ICLs showed a significant
enrichment of UHRF1 in a dose-dependent manner in both repli-
cated and unreplicated sites of ICLs (Figure 1F). These results
suggested that UHRF1 is recruited to sites of DNA ICLs in vivo.
UHRF1 Binds Directly to ICLs through the SRA Domain
Although UHRF1 is shown to be associated with ICLs in nuclear
extracts and in vivo, such association could be mediated
by other factors. Therefore, we tested whether UHRF1 directly
bound DNA ICLs. An MBP-UHRF1 recombinant protein was
purified via amylose beads and incubated with DNA containing
psoralen- or cisplatin-induced ICLs. As shown in Figure 2A,
MBP-UHRF1 retained specifically crosslinked, but not control,
DNA, whereas maltose-binding protein (MBP) alone showed
no detectable binding to either DNA probes.
We further validated the affinity of UHRF1 to ICL substrates in
a competition assay. Immobilized MBP-UHFR1 fusion protein
was pre-incubated with 32P-labeled oligonucleotide containing
psoralen or cisplatin ICLs followed by the addition of increasing
amounts of unlabeled ICL-containing or control oligo (Figures 2B
and 2C). The results showed that the ICL-containing oligonucle-
otide was much more efficient in competing for UHRF1 binding
than the control. These results demonstrated that UHRF1 ex-
hibits direct affinity for DNA ICLs.
UHRF1 contains five conserved motifs that include UBL, tan-
dem tudor (TUDOR), plant homeodomain (PHD), SET and RING-
associated (SRA), and RING domains (Figure 2D). To determine
whether the ICL-binding activity could be localized to a specific
region or domain(s), we generated five truncation mutants. Each
mutant has one of the five conserved domains removed.
MBP-fusion proteins of each mutant were purified and tested
in the ICL pull-down assay with psoralen or cisplatin ICL DNA.
As shown in Figure 2E, only deletion of the SRA domain
completely abolished UHRF1 binding to ICL-containing DNA,
indicating that the SRA domain is most critical for UHRF1’s
ability to recognize DNA crosslinking lesions.
Loss of UHRF1 Function Leads to DNA Damage
Sensitivity
The association of UHRF1 with ICL lesions suggested that it may
play a role in cellular response to ICLs. To test this premise, wehe presence of a single-defined psoralen-ICL is indicated. The arrow indicates
R amplification. Bottom: eChIP assay measuring the recruitment of the UHRF1
riments.
. The presence of random cisplatin-ICLs is illustrated. Small arrows indicate the
the UHRF1 protein in 293 and 293EBNA cells. Numbers of cisplatin ICL per kb
iments.
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Figure 2. UHRF1 Binds to ICLs Directly to ICLs through the SRA Domain
(A) Binding of MBP-tagged UHRF1 to crosslinked (XL) and control (Ctrl) probes with 32P end-labeling (left). MBP or MBP-UHRF1 were immobilized onto amylose
beads and incubated with PSO ICL- or cisplatin ICL-containing probes. Bound DNA was eluded with maltose, and resolved on 2% agarose gel. Aliquots of
amylose beads bound proteins were eluded and resolved by PAGE as the loading control (right).
(B) Binding affinity of UHRF1 toward psoralen DNA ICL. Left: MBP-tagged UHRF1 was preincubated with 32P-labeled PSO-ICL probe prior to the addition of cold
PSO-ICL competitor probe (top) or cold control competitor probe (bottom) with the indicated concentrations. Bound DNA was recovered by amylose beads and
resolved on 2% agarose gel to reveal the retention of 32P-labeled PSO-ICL probe. Right: Quantification of relative ICL retention as a function of excess amount of
control or ICL competitors. Error bars are SD from three independent experiments.
(C) Binding affinity of UNRF1 toward cisplatin DNA ICL performed as in (B).
(D) Illustration of UHRF1 domain structure and UHRF1 domain deletion mutants. UBL, ubiquitin-like domain; TUDOR, tandem tudor domain; PHD, plant
homeodomain; SRA, SET and RING-associated domain.
(E) Binding of UHRF1 domain deletion mutants to PSO-ICL and cisplatin-ICL probes. Bottom: Input recombinant proteins for the ICL binding assay as
performed in (A).established a UHRF1 conditional allele in the HCT116 back-
ground via somatic cellular targeting (Figure S2A). Although ho-
mozygous deletion of UHRF1 leads to severe proliferation defect
(Figures S2B–S2D), we obtained two independent hypomorphic
mutants (UHRF1/Neo-1 andUHRF1/Neo-2) in which oneUHRF1
allele was inactivated and the other was rendered hypomorphic
by the insertion of a NeoR cassette upstream of exon 4. As a
result, both hypomorphic mutants express UHRF1 protein at
significantly reduced levels in comparison to wild-type (WT)
UHRF1+/+ cells but maintain normal growth characteristics.
Next, we analyzed UHRF1/Neo-1 and UHRF1/Neo-2 mutants
for their sensitivity toDNAdamageexposure.As shown inFigures1960 Cell Reports 10, 1957–1966, March 31, 2015 ª2015 The Author3A–3C, both hypomorphic mutants displayed increased sensi-
tivity tomitomycinC,UV, orPso-UVA treatments.Complementa-
tion of both mutants withWT UHFR1 restored cell survival to that
of theWTHCT116 cells. Knockdown of UHRF1 in 293T andHeLa
cells also significantly increased their sensitivity to mitomycin C
and UV (Figures S2E and S2F). When compared to FANCL- or
SLX4-null mutants, UHRF1 hypomorphic cells are considerably
less sensitive (Figures 5B and 5C). However, in comparison to
isogenic FANCM/ and FAAP24/mutants, the UHRF1 hypo-
morphic mutants displayed similar sensitivities to mitomycin C
(Figure S2G). These result suggested that UHRF1 is functionally
involved in cellular resistance against DNA damage.s
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Figure 3. UHRF1 Deficiency Sensitizes Cells to DNA Damage and Attenuates Lesion Processing
Clonogenic survival of UHRF1/Neo-1 and UHRF1/Neo-2 and their complemented derivatives exposed to mitomycin C (A), UV (B), and psoralen plus UVA (C)
treatment. Error bars are SD across three or more technical replicates.
(D) Formation of mitomycin C (MMC)-induced gH2AX nuclear foci in WT (UHRF1+/+) and hypomorphic mutant (UHRF1/Neo-1 and UHRF1/Neo-2) cells 12 hr after
treatment.
(E) Percentage of gH2AX foci-positive nuclei fromMMC-treatedUHRF1+/+ andUHRF1/Neo-1 andUHRF1/Neo-2 cells at indicated time points afterMMC exposure.
(F) Immunoblot detecting gH2AX in UHRF1+/+ and UHRF1/Neo cells treated with mitomycin C and collected at indicated time points.As an important factor in maintaining DNA cytosine methyl-
ation (Bostick et al., 2007), the UHRF1 RING-domain-dependent
E3 ligase activity has been found essential for the recruitment
of DNMT1 and subsequent replication of cytosine methylation
patterns (Nishiyama et al., 2013). When two UHRF1 E3 ligase
mutants, C724A and H741A (Jenkins et al., 2005), were used
to complement the UHRF1/Neo cells, the DNA damage resis-
tance was largely restored (Figure S2H). This result indicated
that disruption of methylation maintenance was unlikely the pri-
mary cause for the damage sensitivity phenotype and thatCellUHRF1 may have functions directly linked to the DNA damage
response.
The DNA damage sensitive phenotype suggests that UHRF1
mutant cells may be deficient in the removal of ICL lesions
efficiently, resulting in a higher level of residue damage and
decreased cell survival. Thus, we analyzed gH2AX foci formation
in UHRF1/Neo and UHRF1+/+ cells exposed to mitomycin C.
Under unperturbed growth conditions, UHRF1/Neo cells exhibit
a higher percentage of gH2AX foci-positive nuclei (Figure 3D).
This result suggests that cells lacking UHRF1 function indeedReports 10, 1957–1966, March 31, 2015 ª2015 The Authors 1961
accumulate DNA damage. However, upon mitomycin C
treatment, both the UHRF1/Neo-1 and UHRF1/Neo-2 mutants
showed a markedly reduced gH2AX foci formation in compari-
son to WT UHRF1+/+ cells, especially at later time points (12
and 24 hr; Figure 3E). Similarly, immunoblotting of gH2AX (Fig-
ure 3F) also confirmed the attenuated onset of gH2AX induction
upon DNA damage and a higher level of basal level gH2AX in the
absence of exogenous DNA damage. To further validate these
results, we analyzed 53BP1 foci formation in UHRF1/Neo
mutants exposed to mitomycin C. Consistent with the gH2AX
results, mitomycin C-mediated 53BP1 foci formation also de-
creases inUHRF/Neomutant cells (Figures S3A and S3B). These
results suggest that UHRF1 plays a role in the repair of both
endogenous and exogenous lesions.
UHRF1 Function Is Involved in the Recruitment of ICL
Damage-Processing Activities
Because the formation of DNA strand breaks is a primary signal
that triggers the accumulation of gH2AX and 53BP1, attenuated
foci formation in UHRF1-deficient cells may reflect a potential
lackof ICL processing that createsDNAstrandbreaks. Therefore,
we tested the premise that impaired recruitment of lesion-
processing nuclease activities contributes to the diminished
inductionofgH2AXand53BP1 foci and to theDNAdamagesensi-
tivity phenotype fromUHRF1-deficiency. First, we askedwhether
UHRF1 interacts directly with ERCC1-XPF or MUS81-EME1, two
structure-specific endonucleases that are required in processing
ICL lesions. As shown by coimmunoprecipitation of both tagged
andendogenousproteins (Figures 4A–4CandS3B),UHRF1 inter-
actswithbothERCC1/XPFandMUS81/EME1.Moreover, recom-
binant MBP-UHRF1 was able to pull down MUS81 and ERCC1
from HeLa nuclear extract. An N-terminal UHRF1 truncation
lacking the SRA and RING domains disrupted the association
with both ERCC1 and MUS81, whereas a C-terminal truncation
retaining these domains was able to bind MUS81 and ERCC1
(Figure 4D). Together, these results suggest a direct interaction
between UHRF1 and ICL-processing nucleases.
Both ERCC1-XPF and MUS81-EME1 are known to be associ-
ated with a common scaffold protein, SLX4/FANCP (Fekairi
et al., 2009; Mun˜oz et al., 2009; Svendsen et al., 2009). We asked
whether the observed interactions are mediated by SLX4. To
this end, we generated a HeLa SLX4-null mutant and examined
the interactions between UHRF1 and the two nucleases by co-
immunoprecipitation (Figure 4E). We found that deletion of
SLX4 does not abolish the interactions, suggesting that binding
of UHRF1 to the lesion-processing nucleases is independent of
SLX4. Consistently, reciprocal immunoprecipitation between
Myc-SLX4 and SFB-UHRF1 showed no detectable interaction
between the two proteins (Figure 4F).
Given UHRF1’s lesion-binding affinity and its direct interac-
tions with lesion-processing nucleases, a likely function for
UHRF1 in DNA damage response may be to recruit lesion-pro-
cessing nucleases to the site of damage. We tested this notion
by eChIP in the UHRF1/Neo hypomorphic mutant cells. As
shown in Figure 4G, enrichment of Mus81 onto cisplatin-ad-
ducted DNA substrate is significantly reduced in both UHRF1
mutants in comparison to the parental UHRF+/+ cells. Similarly,
enrichment of ERCC1 is also reduced in the UHRF1/Neo hypo-1962 Cell Reports 10, 1957–1966, March 31, 2015 ª2015 The Authormorphic mutant cells (Figure 4H), suggesting a role for UHRF1
in the processing of ICL lesions by recruiting structure-specific
endonucleases.
UHRF1 Function in DNA Damage Response Is Not
Redundant with the FA Pathway
Although UHRF1 interacts with ERCC1 and MUS81 indepen-
dently of SLX4, it is unclear whether UHRF1 is functionally
distinct from the FA pathway. To address this question, we
tested whether activation of the FA pathway is compromised in
the UHRF1-deficient cells (Figure 5A). We found that both
UHRF1 hypomorphic mutants exhibited mitomycin C-induced
FANCD2 monoubiquitination similar to WT controls, suggesting
that activation of the FA pathway is not significantly affected
by UHRF1 depletion.
To functionally determine whether UHRF1’s role in DNA dam-
age response is distinct from the FA mechanism, we knocked
down UHRF1 in SLX4/ HeLa cells and analyzed clonogenic
survival against cisplatin (Figures 5B and S4A). In comparison
to cells lacking UHRF1 or SLX4 alone, the combined loss of
UHRF1 and SLX4 acquired additional hypersensitivity to DNA
damage, suggesting that the damage repair function of UHRF1
is parallel to that of SLX4.
To substantiate this result further, FANCL/ cells constructed
in HeLa background were depleted of UHRF1 via small hairpin
RNA (shRNA) knockdown. Clonogenic survival indicated that
UHRF1 knockdown in HeLa cells yielded increased sensitivity
to mitomycin C, although it was less profound than in FANCL
knockout cells. However, UHRF1 knockdown in FANCL/
HeLa cells produced enhanced sensitivity to mitomycin C
(Figures 5C and S4B). Consistently, UHRF1 knockdown in
FANCL/ HCT116 cells also rendered additional cell killing
by mitomycin C (Figure 5D). These results suggest that UHRF1
provides ICL repair functions independent of the FA pathway
components most likely through its lesion-binding capability
and recruitment of lesion-processing nucleases.
DISCUSSION
Each type of DNA damage, such as bulky adducts, mismatches,
and DNA double-strand breaks, is recognized by a lesion-spe-
cific damage-binding protein to initiate the repair process. In
the case of DNA ICLs, it has been unclear whether an ICL-spe-
cific lesion recognition factor exists. We approached this ques-
tion by biochemical purification of ICL binding affinities from
nuclear extracts and identified UHRF1. Previous studies have
shown that loss of UHRF1 renders cells sensitive to DNA-dam-
age exposure (Jenkins et al., 2005; Muto et al., 2002). In this
study, we constructed genetic and knockdown mutants of
UHRF1 and analyzed its function in DNA damage response.
Our experimental evidence suggests that UHRF1 possesses ac-
tivities recognizing ICL lesions while also interacting with lesion
processing nucleases, suggesting that it is a candidate factor
in promoting DNA damage processing.
DNA Damage Affinity of UHRF1
The lesion-binding ability of UHRF1 was examined by three
independent approaches: cell biology with laser-localized ICLss
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Figure 4. UHRF1-Dependent Recruitment of ICL-Processing Nucleases
(A) Co-immunoprecipitation between UHRF1 and ICL-processing nucleases. 293T cells co-transfected with SFB-tagged UHRF1 and indicated nucleases were
co-immunoprecipitated with anti-Flag antibody and immunoblotted (IB) with indicated antibodies. The asterisk marks a nonspecific band in 293 cells.
(B) Immunoblot detecting indicated proteins from control (IgG) and UHRF1 co-immunoprecipitation of MMC-treated 293T cells.
(C) Immunoblot detecting UHRF1 from control (IgG), MUS81, and ERCC1 antibody co-immunoprecipitation of MMC-treated 293T cells.
(D) Pull down of MUS81 and ERCC1 from HeLa extract. MBP-UHRF1 and two UHRF1 truncations, UHRF1C (DUBL-TUDOR-PHD) and MBP-UHRF1N (DSRA-
RING), were immobilized onto amylose beads and incubated with HeLa nuclear extract. Bound proteins were eluted with maltose for immunoblot detection of
ERCC1 and MUS81.
(E) Co-immunoprecipitation between UHRF1 and ICL-processing nucleases. SLX4-null HeLa cells co-transfected with SFB-tagged UHRF1 and indicated
nucleases were in co-immunoprecipitation with anti-FLAG antibody as immunoblotted with the indicated antibodies.
(F) Reciprocal immunoprecipitation between UHRF1 and SLX4. 293T cells co-transfected with SFB-tagged UHRF1 and Myc-tagged SLX4 were subjected to
reciprocal IP with anti-Myc and anti-Flag antibodies.
(G) eChIP assay measuring the recruitment of Mus81 to cisplatin ICLs inUHRF1+/+,UHRF1/Neo-1, andUHRF1/Neo-2 cells. Error bars are SD derived from three
independent experiments.
(H) eChIP assay measuring the recruitment of ERCC1 to cisplatin ICLs inUHRF1+/+,UHRF1/Neo-1, andUHRF1/Neo-2 cells. Error bars are SD derived from three
independent experiments.
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Figure 5. UHRF1-Dependent Recruitment of ICL-Processing Nucleases
(A) Immunoblots detecting FANCD2 monoubiquitination in cells with indicated genotypes treated or mock-treated with MMC (300 ng/ml). L and S represent
monoubiquitinated and native forms of FANCD2, respectively. Note that the tubulin loading control is shared with Figure 3F because they are from the same blot.
(B) Clonogenic survival of SLX/HeLa cells infected with lentivirus expressing control (Ctrl) or UHRF1 shRNA (sh3 and sh4).
(C) Clonogenic survival of FANCL/HeLa cells with UHRF1 knockdown (UHRF1 sh3 and sh4).
(D) Clonogenic survival of HCT116 (WT) and FANCL/HCT116 cells with UHRF1 knockdown (UHRF1 sh3 and sh4).
(E) A model depicting UHRF1 acts as a damage recognition protein and nuclease scaffold in parallel to the FA-SLX4-mediated ICL DNA damage response.in vivo, ChIP-based ICL damage enrichment at the molecular
level, and biochemical binding assays in vitro. Results from these
experiments consistently indicated that UHRF1 exhibited strong
and direct affinity toward DNA ICL damage. The structural basis
for UHRF1’s ICL binding affinity is not clear. Using a panel of
UHRF1 domain deletion mutants, we found that the SRA domain
is required for the binding to ICL lesions (Figure 2E). The SRA1964 Cell Reports 10, 1957–1966, March 31, 2015 ª2015 The Authordomain has been reported to exhibit a moderate affinity toward
hemimethylated CpG duplex DNA and was considered as a
hemimethylation recognition mechanism for the recruitment of
DNMT1 (Avvakumov et al., 2008). However, recent studies indi-
cate that the Tudor and E3 ligase domains playmore critical roles
in directing DNMT1 to hemimethylated DNA (Arita et al., 2012;
Liu et al., 2013; Nishiyama et al., 2013). It is conceivable thats
the UHRF1 SRA domain exhibits structural flexibility and can
recognize a broad range of damage-induced helix distortions,
thus enabling it to bind to a variety of damages.
UHRF1 as a Nuclease Scaffold
Lack of DNA damage-induced gH2AX and 53BP1 foci accu-
mulation in the UHRF1 mutant cells hinted at an impaired
lesion processing that could arise from a deficit of nuclease
activity at the site of the lesion. Accordingly, we examined
UHRF1 protein-protein interactions and found both ERCC1/
XPF and MUS81/EME1 are associated with UHRF1, suggest-
ing that structure-specific endonucleases interact with UHRF1
in their heterodimeric forms. A protein-protein interaction be-
tween UHRF1 and EME1 was previously detected by a yeast
two-hybrid screen (Mistry et al., 2008). This observation also
suggests a direct interaction between UHRF1 and lesion-pro-
cessing enzymes.
The functionality of the interactions is supported by the
reduced nuclease recruitment to the sites of DNA lesions. The
dual activities of UHRF1 in damage-binding and nuclease asso-
ciation functions may allow it to recruit lesion-processing activ-
ities to promote DNA damage removal. Such a property is akin
to the NER protein XPA, which has lesion-binding affinity and
acts as a scaffold for nuclease recruitment (Li et al., 1994; Orelli
et al., 2010). The dual activities of UHRF1 is also functionally
analogous to that of budding SAW1 protein which binds flap
structures and promotes the recruitment of Rad1/Rad10 through
direct interactions (Li et al., 2008).
Interestingly, the nuclease recruitment function of UHRF1
seems non-epistatic to that of SLX4/FANCP. This is supported
by the experiments examining DNA damage sensitivity in cells
with combined UHRF1 and SLX4 depletions. SLX4 is considered
a main downstream effector of FA pathway activation, which is
presumed to guide lesion-processing and Holliday junction res-
olution lesion-processing nucleases (Hodskinson et al., 2014;
Klein Douwel et al., 2014; Wan et al., 2013). The enhanced
phenotype from a combined loss of SLX4 and UHRF1 suggests
that UHRF1 provides a parallel mechanism for the enrichment of
lesion processing nucleases (Figure 5E). Such a notion is further
supported by the epistatic analyses indicating that UHRF1
function is non-redundant to FANCL. However, given the early
lesion recognition function of UHRF1, it remains possible that
a portion of UHRF1 function is projected through promoting
FA pathway activation (Liang et al., 2015). Together, our findings
revealed a DNA damage response function of UHRF1 and an
FA-pathway-independent mechanism of nuclease recruitment
to the site of lesions.
EXPERIMENTAL PROCEDURES
Antibodies and Plasmids
Commercial antibodies used in this study were purchased as follows, anti-
human UHRF1 (Abgent, NP-037414), anti-gH2AX (Upstate, 07-164), anti-hu-
man mus81 (Thermo Scientific, MA1-5837), anti-human ERCC1 (NeoMarker,
MS-671-P0), and anti-MCM5 (Bethyl Laboratories, A300-195A). WT UHRF1
cDNA, DPHD, DSRA, and DRING constructs in pPyCAGIP-FLAG vector
were a kind gift from Dr. Jiemin Wong. pENTER-UHRF1C724A and
pENTER-UHRF1H741A were a kind gift from Dr. Yonchu Jenkins (Rigel
Pharmaceuticals).CelleChIP Assay
The eChIP assay protocol and substrate preparation were described earlier
(Shen et al., 2009). Cisplatin-adducted plasmid substrates were prepared by
incubating the pOriP plasmid with different dose of cisplatin for 3 hr at 37C
in the dark.
Clonogenic Survival Assay
Prior to treatment, 1–33 105 cells were seeded in a 100mmculture plate 24 hr.
Cells were exposed to various doses of DNA-damage agents for 1 hr and then
seeded with appropriate cell number in triplicates for each dosage. After
14 days, colonies were fixed with 6% glutaraldehyde (v/v) and stained with
0.5% crystal violet (w/v).
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.03.038.
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